Učitavanje...
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success in the treatment of different cancer types. Yet, only a subset of patients derive clinical benefit. It is thus critical to und...
Spremljeno u:
| Izdano u: | Nat Rev Cancer |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6705396/ https://ncbi.nlm.nih.gov/pubmed/30755690 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41568-019-0116-x |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|